FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Kazuo Nakamura

Research Profile

Chemicals & Drugs

Disorders

Anatomy

Concepts & Ideas

Biological Models

Co-author Network

Publications

TOP 3
Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui
Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease.
Sho-ichi Yamagishi; Hisashi Adachi; Takanori Matsui; Kazuo Nakamura; Mika Enomoto; Ako Fukami; Maki Otsuka; Shun-ichi Kumagae; Yasuki Nanjo; Tsutomu Imaizumi
Decreased high-density lipoprotein cholesterol level is an independent correlate of circulating tumor necrosis factor-alpha in a general population.
Sho-ichi Yamagishi; Hisashi Adachi; Takanori Matsui; Kazuo Nakamura; Masayoshi Takeuchi; Mika Enomoto; Ako Fukami; Maki Otsuka; Shun-ichi Kumagae; Yasuki Nanjo; Shin-ichiro Ueda; Tsutomu Imaizumi
Low-density lipoprotein levels are one of the independent determinants of circulating levels of advanced glycation end products in nondiabetic subjects.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Kazuo Nakamura (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui
Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease.
Pharmacological research : the official journal of the Italian Pharmacological Society 2009;60(3):174-8.
2009: Sho-ichi Yamagishi; Hisashi Adachi; Takanori Matsui; Kazuo Nakamura; Mika Enomoto; Ako Fukami; Maki Otsuka; Shun-ichi Kumagae; Yasuki Nanjo; Tsutomu Imaizumi
Decreased high-density lipoprotein cholesterol level is an independent correlate of circulating tumor necrosis factor-alpha in a general population.
Clinical cardiology 2009;32(9):E29-32.
2009: Sho-ichi Yamagishi; Hisashi Adachi; Takanori Matsui; Kazuo Nakamura; Masayoshi Takeuchi; Mika Enomoto; Ako Fukami; Maki Otsuka; Shun-ichi Kumagae; Yasuki Nanjo; Shin-ichiro Ueda; Tsutomu Imaizumi
Low-density lipoprotein levels are one of the independent determinants of circulating levels of advanced glycation end products in nondiabetic subjects.
Clinical cardiology 2009;32(9):E12-5.
2009: Kazuo Nakamura; Hisashi Adachi; Takanori Matsui; Yayoi Kurita; Masayoshi Takeuchi; Sho-ichi Yamagishi
Independent determinants of soluble form of receptor for advanced glycation end products in elderly hypertensive patients.
Metabolism: clinical and experimental 2009;58(3):421-5.
2009: Sho-ichi Yamagishi; Takanori Matsui; Katsuhiko Takenaka; Kazuo Nakamura; Masayoshi Takeuchi; Hiroyoshi Inoue
Pigment epithelium-derived factor (PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs).
Diabetes/metabolism research and reviews 2009;25(3):266-71.
2009: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; K Takenaka
Administration of pigment epithelium-derived factor prolongs bleeding time by suppressing plasminogen activator inhibitor-1 activity and platelet aggregation in rats.
Clinical and experimental medicine 2009;9(1):73-6.
2009: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura
Atheroprotective properties of pigment epithelium-derived factor (PEDF) in cardiometabolic disorders.
Current pharmaceutical design 2009;15(9):1027-33.
2009: Kazuo Nakamura; Sho-ichi Yamagishi; Hisashi Adachi; Yayoi Kurita-Nakamura; Takanori Matsui; Hiroyoshi Inoue
Serum levels of pigment epithelium-derived factor (PEDF) are positively associated with visceral adiposity in Japanese patients with type 2 diabetes.
Diabetes/metabolism research and reviews 2009;25(1):52-6.
2008: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura
Possible link of food-derived advanced glycation end products (AGEs) to the development of diabetes.
Medical hypotheses 2008;71(6):876-8.
2008: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; So Ueda; Yoshihiro Noda; Tsutomu Imaizumi
Pigment epithelium-derived factor (PEDF): its potential therapeutic implication in diabetic vascular complications.
Current drug targets 2008;9(11):1025-9.
2008: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura
Blockade of the advanced glycation end products (AGEs) and their receptor (RAGE) system is a possible mechanism for sustained beneficial effects of multifactorial intervention on mortality in type 2 diabetes.
Medical hypotheses 2008;71(5):749-51.
2008: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura
Possible molecular mechanisms by which angiotensin II type 1 receptor blockers (ARBs) prevent the development of atrial fibrillation in insulin resistant patients.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2008;40(9):640-4.
2008: Takafumi Yoshida; Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Tsutomu Imaizumi; Masayoshi Takeuchi; Hironori Koga; Takato Ueno; Michio Sata
Pigment epithelium-derived factor (PEDF) ameliorates advanced glycation end product (AGE)-induced hepatic insulin resistance in vitro by suppressing Rac-1 activation.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2008;40(9):620-5.
2008: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura
Possible involvement of tobacco-derived advanced glycation end products (AGEs) in an increased risk for developing cancers and cardiovascular disease in former smokers.
Medical hypotheses 2008;71(2):259-61.
2008: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Seiji Ueda; Kei Fukami; Seiya Okuda
Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications.
Expert opinion on investigational drugs 2008;17(7):983-96.
2008: Takafumi Yoshida; Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Takato Ueno; Masayoshi Takeuchi; Michio Sata
Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-gamma activation.
The Journal of international medical research 2008;36(2):237-43.
2008: Katsuhiko Takenaka; Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Yuko Jinnouchi; Yumiko Yoshida; Shin-ichiro Ueda; Yoshio Katsuki; Yousuke Katsuda; Tsutomu Imaizumi
Pigment epithelium-derived factor (PEDF) administration inhibits occlusive thrombus formation in rats: a possible participation of reduced intraplatelet PEDF in thrombosis of acute coronary syndromes.
Atherosclerosis 2008;197(1):25-33.
2008: Kazuo Nakamura; Sho-ichi Yamagishi; Hisashi Adachi; Takanori Matsui; Yayoi Kurita-Nakamura; Masayoshi Takeuchi; Hiroyoshi Inoue; Tsutomu Imaizumi
Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.
Diabetes/metabolism research and reviews 2008;24(2):109-14.
2008: Sho-ichi Yamagishi; Seiji Ueda; Kazuo Nakamura; Takanori Matsui; Seiya Okuda
Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications.
Current pharmaceutical design 2008;14(25):2613-8.
2008: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Masayoshi Takeuchi; Hiroyoshi Inoue
Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation.
Protein and peptide letters 2008;15(8):850-3.
2008: Sho-ichi Yamagishi; Seiji Ueda; Takanori Matsui; Kazuo Nakamura; Seiya Okuda
Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy.
Current pharmaceutical design 2008;14(10):962-8.
2008: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; So Ueda; Yoshihiro Noda; Tsutomu Imaizumi
Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease.
Cardiovascular therapeutics 2008;26(1):50-8.
2008: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Yoshihiro Noda; Tsutomu Imaizumi
Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication.
Current pharmaceutical design 2008;14(5):487-95.
2008: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui
Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine.
Current medicinal chemistry 2008;15(2):172-7.
2008: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Hiroyoshi Inoue; Masayoshi Takeuchi; Seiji Ueda; Seiya Okuda; Tsutomu Imaizumi
Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species.
Ophthalmic research 2008;40(1):10-5.
2008: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Hiroyoshi Inoue; Masayoshi Takeuchi; Seiji Ueda; Kei Fukami; Seiya Okuda; Tsutomu Imaizumi
Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression.
Microvascular research 2008;75(1):130-4.
2007: Takanori Matsui; Sho-ichi Yamagishi; Kazuo Nakamura; Hiroyoshi Inoue
Bay w 9798, a dihydropyridine structurally related to nifedipine with no calcium channel-blocking properties, inhibits tumour necrosis factor-alpha-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation.
The Journal of international medical research 2007;35(6):886-91.
2007: Sho-ichi Yamagishi; Hisashi Adachi; Masayoshi Takeuchi; Mika Enomoto; Kumiko Furuki; Takanori Matsui; Kazuo Nakamura; Tsutomu Imaizumi
Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2007;39(11):845-8.
2007: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura
Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Current drug targets 2007;8(10):1138-43.
2007: Yuko Jinnouchi; Sho-ichi Yamagishi; Takanori Matsui; Katsuhiko Takenaka; Yumiko Yoshida; Kazuo Nakamura; Shin-ichiro Ueda; Tsutomu Imaizumi
Administration of pigment epithelium-derived factor (PEDF) inhibits cold injury-induced brain edema in mice.
Brain research 2007;1167():92-100.
2007: Yumiko Yoshida; Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Tsutomu Imaizumi; Koichi Yoshimura; Ryoji Yamakawa
Positive correlation of pigment epithelium-derived factor and total antioxidant capacity in aqueous humour of patients with uveitis and proliferative diabetic retinopathy.
The British journal of ophthalmology 2007;91(9):1133-4.
2007: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui
Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders.
Current molecular medicine 2007;7(5):463-9.
2007: Takanori Matsui; Sho-ichi Yamagishi; Seiji Ueda; Kazuo Nakamura; Tsutomu Imaizumi; Masayoshi Takeuchi; Hiroyoshi Inoue
Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation.
The Journal of international medical research 2007;35(4):482-9.
2007: Sho-ichi Yamagishi; Takanori Matsui; Shin-Ichiro Ueda; Kazuo Nakamura; Tsutomu Imaizumi
Advanced glycation end products (AGEs) and cardiovascular disease (CVD) in diabetes.
Cardiovascular & hematological agents in medicinal chemistry 2007;5(3):236-40.
2007: Yuichiro Higashimoto; Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Masayoshi Takeuchi; Masato Noguchi; Hiroyoshi Inoue
In vitro selection of DNA aptamers that block toxic effects of AGE on cultured retinal pericytes.
Microvascular research 2007;74(1):65-9.
2007: Kazuo Nakamura; Sho-ichi Yamagishi; Hisashi Adachi; Yayoi Kurita-Nakamura; Takanori Matsui; Takafumi Yoshida; Akira Sato; Tsutomu Imaizumi
Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease.
Diabetes/metabolism research and reviews 2007;23(5):368-71.
2007: Kazuo Nakamura; Sho-ichi Yamagishi; Takanori Matsui; Takafumi Yoshida; Katsuhiko Takenaka; Yuko Jinnouchi; Yumiko Yoshida; Shin-ichiro Ueda; Hisashi Adachi; Tsutomu Imaizumi
Pigment epithelium-derived factor inhibits neointimal hyperplasia after vascular injury by blocking NADPH oxidase-mediated reactive oxygen species generation.
The American journal of pathology 2007;170(6):2159-70.
2007: Yumiko Yoshida; Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Tsutomu Imaizumi; Koichi Yoshimura; Ryoji Yamakawa
Positive correlation between pigment epithelium-derived factor and monocyte chemoattractant protein-1 levels in the aqueous humour of patients with uveitis.
The British journal of ophthalmology 2007;91(6):737-8.
2007: Kazuo Nakamura; Sho-ichi Yamagishi; Takafumi Yoshida; Takanori Matsui; Tsutomu Imaizumi; Hiroyoshi Inoue; Michio Sata
Hydrogen peroxide stimulates pigment epithelium-derived factor gene and protein expression in the human hepatocyte cell line OUMS-29.
The Journal of international medical research 2007;35(3):427-32.
2007: Kazuo Nakamura; Sho-ichi Yamagishi; Hisashi Adachi; Yayoi Kurita-Nakamura; Takanori Matsui; Takafumi Yoshida; Tsutomu Imaizumi
Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.
Molecular medicine (Cambridge, Mass.) 2007;13(3-4):185-9.
2007: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Takafumi Yoshida; Masayoshi Takeuchi; Tsutomu Imaizumi
Pigment epithelium-derived factor (PEDF) blocks advanced glycation end product (AGE)-induced angiogenesis in vitro.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2007;39(3):233-5.
2007: Yumiko Yoshida; Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Tsutomu Imaizumi; Koichi Yoshimura; Ryoji Yamakawa
Increased levels of pigment epithelium-derived factor in aqueous humor of patients with uveitis.
The British journal of ophthalmology 2007;91(2):149-50.
2007: Sho-ichi Yamagishi; Seiji Ueda; Takanori Matsui; Kazuo Nakamura; Tsutomu Imaizumi; Masayoshi Takeuchi; Seiya Okuda
Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties.
Protein and peptide letters 2007;14(8):832-5.
2007: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Tsutomu Imaizumi
Pigment epithelium-derived factor (PEDF) inhibits angiotensin II-induced smooth muscle cell proliferation through its anti-oxidative properties.
Protein and peptide letters 2007;14(6):615-7.
2007: Takanori Matsui; Sho-ichi Yamagishi; Kazuo Nakamura; Hiroyoshi Inoue; Masayoshi Takeuchi
Nifedipine, a calcium-channel blocker, inhibits advanced glycation end-product-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells.
The Journal of international medical research 2007;35(1):107-12.
2007: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Hiroyoshi Inoue; Masayoshi Takeuchi
Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.
Medical hypotheses 2007;69(3):666-8.
2007: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Hiroyoshi Inoue
A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders.
Medical hypotheses 2007;69(2):338-40.
2007: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Takafumi Yoshida; Masayoshi Takeuchi; Hiroyoshi Inoue; Yumiko Yoshida; Tsutomu Imaizumi
Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats.
Ophthalmic research 2007;39(2):92-7.
2007: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura
Prevention of diabetic vascular calcification by nifedipine, a dihydropyridine-based calcium channel blocker.
Medical hypotheses 2007;68(5):1096-8.
2007: Sho-ichi Yamagishi; Kazuo Nakamura
Revival of nifedipine, a dihydropyridine-based calcium blocker.
Medical hypotheses 2007;68(3):565-7.
2006: Takafumi Yoshida; Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Tsutomu Imaizumi; Masayoshi Takeuchi; H Koga; Takato Ueno; Michio Sata
Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation.
Diabetologia 2006;49(12):3094-9.
2006: Takanori Matsui; Sho-ichi Yamagishi; Kazuo Nakamura; Hiroyoshi Inoue
Azelnidipine, a new long-acting calcium-channel blocker, inhibits tumour necrosis factor-alpha-induced monocyte chemoattractant protein-1 expression in endothelial cells.
The Journal of international medical research 2006;34(6):671-5.
2006: Takafumi Yoshida; Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Tsutomu Imaizumi; Hiroyoshi Inoue; Takato Ueno; Michio Sata
Pigment epithelium-derived factor (PEDF) blocks the interleukin-6 signaling to C-reactive protein expression in Hep3B cells by suppressing Rac-1 activation.
Life sciences 2006;79(21):1981-7.
2006: Sho-ichi Yamagishi; Hisashi Adachi; Kazuo Nakamura; Takanori Matsui; Yuko Jinnouchi; Katsuhiko Takenaka; Masayoshi Takeuchi; Mika Enomoto; Kumiko Furuki; Asuka Hino; Yoshiyuki Shigeto; Tsutomu Imaizumi
Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.
Metabolism: clinical and experimental 2006;55(9):1227-31.
2006: Sho-ichi Yamagishi; Seiji Kikuchi; Kazuo Nakamura; Takanori Matsui; T Makino; O Norisugi; Tadamichi Shimizu; Hiroyoshi Inoue; Tsutomu Imaizumi
Pigment epithelium-derived factor (PEDF) blocks angiotensin II-induced T cell adhesion to endothelial cells by suppressing intercellular adhesion molecule-1.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2006;38(8):546-8.
2006: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Yosuke Inagaki; Katsuhiko Takenaka; Yuko Jinnouchi; Yumiko Yoshida; Tetsuro Matsuura; Isao Narama; Yoshihiro Motomiya; Masayoshi Takeuchi; Hiroyoshi Inoue; Akihiko Yoshimura; Richard Bucala; Tsutomu Imaizumi
Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression.
The Journal of biological chemistry 2006;281(29):20213-20.
2006: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Masayoshi Takeuchi; Tsutomu Imaizumi
Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis.
Microvascular research 2006;72(1-2):86-90.
2006: Sho-ichi Yamagishi; Hisashi Adachi; Akio Abe; Takako Yashiro; Mika Enomoto; Kumiko Furuki; Asuka Hino; Yuko Jinnouchi; Katsuhiko Takenaka; Takanori Matsui; Kazuo Nakamura; Tsutomu Imaizumi
Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome.
The Journal of clinical endocrinology and metabolism 2006;91(6):2447-50.
2006: Takafumi Yoshida; Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Tsutomu Imaizumi; Masayoshi Takeuchi; Takato Ueno; Michio Sata
Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation.
FEBS letters 2006;580(11):2788-96.
2006: Sho-ichi Yamagishi; Seiji Kikuchi; Kazuo Nakamura; Takanori Matsui; Masayoshi Takeuchi; Hiroyoshi Inoue
Pigment epithelium-derived factor (PEDF) blocks angiotensin II-induced T cell proliferation by suppressing autocrine production of interleukin-2.
Medicinal chemistry (Shāriqah (United Arab Emirates)) 2006;2(3):265-9.
2006: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Takafumi Yoshida; Kyoko Shimizu; Yoshiaki Takegami; Tadamichi Shimizu; Hiroyoshi Inoue; Tsutomu Imaizumi
Pigment-epithelium-derived factor (PEDF) inhibits angiotensin-II-induced vascular endothelial growth factor (VEGF) expression in MOLT-3 T cells through anti-oxidative properties.
Microvascular research 2006;71(3):222-6.
2006: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui
Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy.
Current drug discovery technologies 2006;3(1):83-8.
2006: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Katsuhiko Takenaka; Yuko Jinnouchi; Tsutomu Imaizumi
Cardiovascular disease in diabetes.
Mini reviews in medicinal chemistry 2006;6(3):313-8.
2006: Katsuhiko Takenaka; Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Tsutomu Imaizumi
Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes.
Current neurovascular research 2006;3(1):73-7.
2006: Sho-ichi Yamagishi; Kazuo Nakamura
Telmisartan, its potential therapeutic implications in cardiometabolic disorders.
Recent patents on cardiovascular drug discovery 2006;1(1):79-83.
2006: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura
Atorvastatin and diabetic vascular complications.
Current pharmaceutical design 2006;12(12):1549-54.
2006: Sho-ichi Yamagishi; Kazuo Nakamura; Katsuhiko Takenaka; Takanori Matsui; Hiroyoshi Inoue
Pleiotropic effects of nifedipine on atherosclerosis.
Current pharmaceutical design 2006;12(12):1543-7.
2006: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Masayoshi Takeuchi
Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy.
Medical hypotheses 2006;66(2):273-5.
2006: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; T Sato; Masayoshi Takeuchi
Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver.
Medical hypotheses 2006;66(4):844-6.
2006: Sho-ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; T Sato; Masayoshi Takeuchi
Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
Medical hypotheses 2006;66(5):1019-21.
2005: Katsuhiko Takenaka; Sho-ichi Yamagishi; Yuko Jinnouchi; Kazuo Nakamura; Takanori Matsui; Tsutomu Imaizumi
Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells.
Life sciences 2005;77(25):3231-41.
2005: Kazuo Nakamura; Sho-ichi Yamagishi; Yayoi Nakamura; Katsuhiko Takenaka; Takanori Matsui; Yuko Jinnouchi; Tsutomu Imaizumi
Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension.
Microvascular research 2005;70(3):137-41.
2005: Sho-ichi Yamagishi; Masayoshi Takeuchi; Takanori Matsui; Kazuo Nakamura; Tsutomu Imaizumi; Hiroyoshi Inoue
Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression.
FEBS letters 2005;579(20):4265-70.
2005: Sho-ichi Yamagishi; Kazuo Nakamura; Seiji Ueda; Seiya Kato; Tsutomu Imaizumi
Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF.
Cell and tissue research 2005;320(3):437-45.
2005: Sho-ichi Yamagishi; Kazuo Nakamura; Katsuhiko Takenaka; Takanori Matsui; Yuko Jinnouchi; Tsutomu Imaizumi
Pigment epithelium-derived factor (PEDF) promotes growth of pericytes through autocrine production of platelet-derived growth factor-B.
Microvascular research 2005;69(3):128-34.
2005: Sho-ichi Yamagishi; Kazuo Nakamura; Tsutomu Imaizumi
Advanced glycation end products (AGEs) and diabetic vascular complications.
Current diabetes reviews 2005;1(1):93-106.
2005: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Hiroyoshi Inoue
Pigment epithelium-derived factor is a pericyte mitogen secreted by microvascular endothelial cells: possible participation of angiotensin II-elicited PEDF downregulation in diabetic retinopathy.
International journal of tissue reactions 2005;27(4):197-202.
2005: Sho-ichi Yamagishi; Takanori Matsui; Kazuo Nakamura; Masayoshi Takeuchi
Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation.
International journal of tissue reactions 2005;27(4):189-95.
2005: Takanori Matsui; Sho-ichi Yamagishi; Kazuo Nakamura; Seiji Kikuchi; Hiroyoshi Inoue
Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells.
Drugs under experimental and clinical research 2005;31(5-6):215-9.
2005: Kazuo Nakamura; Sho-ichi Yamagishi; Takanori Matsui; Hiroyoshi Inoue
Acarbose, an alpha-glucosidase inhibitor, improves insulin resistance in fructose-fed rats.
Drugs under experimental and clinical research 2005;31(4):155-9.
2005: Sho-ichi Yamagishi; Kazuo Nakamura; Hiroyoshi Inoue
Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.
Medical hypotheses 2005;65(6):1013-5.
2005: Sho-ichi Yamagishi; Kazuo Nakamura; Yuko Jinnouchi; Katsuhiko Takenaka; Tsutomu Imaizumi
Molecular mechanisms for vascular injury in the metabolic syndrome.
Drugs under experimental and clinical research 2005;31(3):123-9.
2005: Sho-ichi Yamagishi; Kazuo Nakamura; Hiroyoshi Inoue
Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders.
Medical hypotheses 2005;65(5):953-5.
2005: Sho-ichi Yamagishi; Kazuo Nakamura; Masayoshi Takeuchi
Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders.
Medical hypotheses 2005;65(2):392-4.
2005: Sho-ichi Yamagishi; Kazuo Nakamura; Hiroyoshi Inoue
Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
Medical hypotheses 2005;65(2):377-9.
2005: Kazuo Nakamura; Sho-ichi Yamagishi; Hiroyoshi Inoue
Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist.
Medical hypotheses 2005;65(1):155-7.
2005: Sho-ichi Yamagishi; Kazuo Nakamura; Masayoshi Takeuchi
Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Medical hypotheses 2005;65(1):152-4.
2005: Sho-ichi Yamagishi; Kazuo Nakamura; Hiroyoshi Inoue; Seiji Kikuchi; Masayoshi Takeuchi
Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients.
Medical hypotheses 2005;64(6):1208-10.
2005: Sho-ichi Yamagishi; Kazuo Nakamura; Hiroyoshi Inoue; Seiji Kikuchi; Masayoshi Takeuchi
Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease.
Medical hypotheses 2005;64(6):1205-7.
2005: Sho-ichi Yamagishi; Kazuo Nakamura; Hiroyoshi Inoue; Masayoshi Takeuchi
Met72Thr polymorphism of pigment epithelium-derived factor gene and susceptibility to age-related macular degeneration.
Medical hypotheses 2005;64(6):1202-4.
2005: Shinjiro Amano; Sho-ichi Yamagishi; Yosuke Inagaki; Kazuo Nakamura; Masayoshi Takeuchi; Hiroyoshi Inoue; Tsutomu Imaizumi
Pigment epithelium-derived factor inhibits oxidative stress-induced apoptosis and dysfunction of cultured retinal pericytes.
Microvascular research 2005;69(1-2):45-55.
2004: Sho-ichi Yamagishi; Riichiro Abe; Yosuke Inagaki; Kazuo Nakamura; Hiroshi Sugawara; Daisuke Inokuma; Hideki Nakamura; Tadamichi Shimizu; Masayoshi Takeuchi; Akihiko Yoshimura; Richard Bucala; Hiroshi Shimizu; Tsutomu Imaizumi
Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling.
The American journal of pathology 2004;165(6):1865-74.
2004: Sho-ichi Yamagishi; Yosuke Inagaki; Kazuo Nakamura; Riichiro Abe; Tadamichi Shimizu; Akihiko Yoshimura; Tsutomu Imaizumi
Pigment epithelium-derived factor inhibits TNF-alpha-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation.
Journal of molecular and cellular cardiology 2004;37(2):497-506.
2004: Sho-ichi Yamagishi; Yosuke Inagaki; Kazuo Nakamura; Tsutomu Imaizumi
Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties.
Journal of cardiovascular pharmacology 2004;43(5):724-30.
2004: Sho-ichi Yamagishi; Kazuo Nakamura; Masayoshi Takeuchi; Tsutomu Imaizumi
Molecular mechanism for accelerated atherosclerosis in diabetes and its potential therapeutic intervention.
International journal of clinical pharmacology research 2004;24(4):129-34.
2003: Sho-ichi Yamagishi; Masayoshi Takeuchi; Yosuke Inagaki; Kazuo Nakamura; Tsutomu Imaizumi
Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.
International journal of clinical pharmacology research 2003;23(4):129-34.
2000: F Ryu; Toshifumi Takahashi; Kazuo Nakamura; Yoshie Takahashi; T Kobayashi; Seiichiro Shida; T Kameyama; Eisuke Mekada
Domain analysis of the tetraspanins: studies of CD9/CD63 chimeric molecules on subcellular localization and upregulation activity for diphtheria toxin binding.
Cell structure and function 2000;25(5):317-27.
2000: Kazuo Nakamura; T Mitamura; Toshifumi Takahashi; T Kobayashi; Eisuke Mekada
Importance of the major extracellular domain of CD9 and the epidermal growth factor (EGF)-like domain of heparin-binding EGF-like growth factor for up-regulation of binding and activity.
The Journal of biological chemistry 2000;275(24):18284-90.